7-chloro-3-(2',2'-diethoxyethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide | 201223-99-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻二嗪
• 英文名称: 7-chloro-3-(2',2'-diethoxyethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
• 英文别名: 7-Chloro-3-(2,2-diethoxyethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide；7-chloro-N-(2,2-diethoxyethyl)-1,1-dioxo-4H-1lambda6,2,4-benzothiadiazin-3-imine；7-chloro-N-(2,2-diethoxyethyl)-1,1-dioxo-4H-1λ6,2,4-benzothiadiazin-3-imine
• CAS: 201223-99-6
• 化学式: C₁₃H₁₈ClN₃O₄S
• 分子量: 347.823
• InChiKey: KMFJDDJKZZYCIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  97.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-chloro-3-(2',2'-diethoxyethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide 在 盐酸 作用下， 反应 0.75h， 以48%的产率得到(R/S)-7-chloro-1-hydroxy-2,3-dihydro-1H-imidazo[2,1-c]-1,2,4-benzothiadiazine 5,5-dioxide
  参考文献：
  名称：

  Effect on insulin release of compounds structurally related to the potassium-channel opener 7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide (BPDZ 73): introduction of heteroatoms on the 3-alkylamino side chain of the benzothiadiazine 1,1-dioxide ring

  摘要：

  7-氯-3-吡啶基（烷基）氨基-4H-1,2,4-苯并噻二嗪-1,1-二氧化物和3-烷基氨基-7-氯-4H-1,2,4-苯并噻二嗪-1,1-二氧化物，其侧链在3位含有一个或多个杂原子，已经合成，以寻找新的有效的KATP通道开放剂。通过测量它们对胰岛素释放过程的抑制活性，将这些化合物作为潜在的胰岛B细胞KATP通道开放剂进行了测试。讨论了3位侧链性质对生物活性的影响。

  DOI：

  10.1211/0022357011776216
• 作为产物：
  描述：

  7-chloro-2,3-dihydro-3-oxo-4H-1,2,4-benzothiadiazine 在 吡啶 、 tetraphosphorus decasulfide 、 碳酸氢钠 作用下， 以 甲醇 、 水 为溶剂， 反应 0.67h， 生成 7-chloro-3-(2',2'-diethoxyethyl)amino-4H-1,2,4-benzothiadiazine 1,1-dioxide
  参考文献：
  名称：

  Effect on insulin release of compounds structurally related to the potassium-channel opener 7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide (BPDZ 73): introduction of heteroatoms on the 3-alkylamino side chain of the benzothiadiazine 1,1-dioxide ring

  摘要：

  7-氯-3-吡啶基（烷基）氨基-4H-1,2,4-苯并噻二嗪-1,1-二氧化物和3-烷基氨基-7-氯-4H-1,2,4-苯并噻二嗪-1,1-二氧化物，其侧链在3位含有一个或多个杂原子，已经合成，以寻找新的有效的KATP通道开放剂。通过测量它们对胰岛素释放过程的抑制活性，将这些化合物作为潜在的胰岛B细胞KATP通道开放剂进行了测试。讨论了3位侧链性质对生物活性的影响。

  DOI：

  10.1211/0022357011776216

文献信息

• Therapeutics for the treatment of glaucoma
  申请人：MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

  公开号：US10981951B2

  公开（公告）日：2021-04-20

  The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.

  本发明提供苯并噻二嗪和色苷衍生物，特别是用于治疗青光眼、视网膜病变、治疗年龄相关性黄斑变性、治疗、稳定和/或抑制血液和淋巴血管生成，并通过向眼睛内给予药学有效量的前药，其中前药特异性调节KATP通道以降低眼内压力。
• NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA
  申请人：Mayo Foundation for Medical Education and Research

  公开号：EP3099304A1

  公开（公告）日：2016-12-07
• THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA
  申请人：Mayo Foundation for Medical Education and Research

  公开号：US20210040148A1

  公开（公告）日：2021-02-11

  The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a K ATP channel to reduce an intraocular pressure.
• US6242443B1
  申请人：——

  公开号：US6242443B1

  公开（公告）日：2001-06-05
• [EN] NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA<br/>[FR] NOUVEAUX AGENTS THÉRAPEUTIQUES POUR LE TRAITEMENT DU GLAUCOME
  申请人：MAYO FOUNDATION

  公开号：WO2015117024A1

  公开（公告）日：2015-08-06

  The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.